StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.57−0.08 (-1.50%)

Close on Nov 17, 2026Market cap $482.87MP/E –Yield –

Valneva operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Valneva's operating cash flow for the twelve months ending Jun 30, 2026 was -€55.69M. For fiscal 2025 it was -€52.89M. The highest annual figure on record is €137.74M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€52.89M–
FY2024Dec 31, 2024-€67.22M–
FY2023Dec 31, 2023-€202.74M–
FY2022Dec 31, 2022-€245.34M-419.0%
FY2021Dec 31, 2021€76.90M-44.2%
FY2020Dec 31, 2020€137.74M+2391.2%
FY2019Dec 31, 2019€5.53M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€13.43M–
Q1 FY2026Mar 31, 2026-€313.00K–
Q4 FY2025Dec 31, 2025-€24.51M-357.3%
Q3 FY2025Sep 30, 2025-€17.44M–
Q2 FY2025Jun 30, 2025-€2.80M–
Q1 FY2025Mar 31, 2025-€8.15M–
Q4 FY2024Dec 31, 2024€9.53M–
Q3 FY2024Sep 30, 2024-€10.48M–
Q2 FY2024Jun 30, 2024-€37.83M–
Q1 FY2024Mar 31, 2024-€28.43M–
Q4 FY2023Dec 31, 2023-€65.91M–
Q3 FY2023Sep 30, 2023-€71.40M–
Q2 FY2023Jun 30, 2023-€41.11M–
Q1 FY2023Mar 31, 2023-€24.33M–
Q4 FY2022Dec 31, 2022-€55.83M-238.0%
Q3 FY2022Sep 30, 2022-€89.29M–
Q2 FY2022Jun 30, 2022-€73.38M-300.0%
Q1 FY2022Mar 31, 2022-€26.85M-156.5%
Q4 FY2021Dec 31, 2021€40.45M–
Q3 FY2021Sep 30, 2021-€47.80M–
Q2 FY2021Jun 30, 2021€36.69M–
Q1 FY2021Mar 31, 2021€47.56M–

More Valneva figures

See a number that looks wrong?